• DRAMP ID

    • DRAMP29202
    • Peptide Name

    • ATN-161
    • Source

    • Synthetic construct
    • Family

    • Not found
    • Gene

    • Not found
    • Sequence

    • PHSCN
    • Sequence Length

    • 5
    • UniProt Entry

    • No entry found
    • Protein Existence

    • Not found
    • Biological Activity

    • Antimicrobial, Antiviral(SARS-CoV-2)
    • Target Organism

      • [Ref.33102950]Virus:SARS-CoV-2:inhibition of replication In VeroE6 cells(IC50=3.16 µM).
    • Hemolytic Activity

      • No hemolysis information or data found in the reference(s) presented in this entry
    • Cytotoxicity

    • No cytotoxicity information found in the reference(s) presented
    • Binding Target

    • Not found
    • Linear/Cyclic

    • Linear
    • N-terminal Modification

    • Acylation
    • C-terminal Modification

    • Amidation
    • Nonterminal Modifications and Unusual Amino Acids

    • None
    • Stereochemistry

    • L
    • Structure

    • Not found
    • Structure Description

    • Not found
    • Helical Wheel Diagram

    • DRAMP29202 helical wheel diagram
    • PDB ID

    • None
    • Predicted Structure

    • There is no predicted structure for DRAMP29202.
    • Formula

    • C21H32N8O8S
    • Absent Amino Acids

    • ADEFGIKLMQRTVWY
    • Common Amino Acids

    • CHNPS
    • Mass

    • 556.59
    • PI

    • 7.12
    • Basic Residues

    • 1
    • Acidic Residues

    • 0
    • Hydrophobic Residues

    • 0
    • Net Charge

    • +1
    • Boman Index

    • -1342
    • Hydrophobicity

    • -1.32
    • Aliphatic Index

    • 0
    • Half Life

      • Mammalian:>20 hour
      • Yeast:>20 hour
      • E.coli:?
    • Extinction Coefficient Cystines

    • 0
    • Absorbance 280nm

    • 0
    • Polar Residues

    • 3

DRAMP29202

    • Mechanism of action

    • The peptide inhibits the spike protein interaction with α5β1 integrin and the interaction between α5β1 integrin and ACE2.
  • ·Literature 1
    • Title

    • The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
    • Reference

    • JACC Basic Transl Sci. 2021 Jan;6(1):1-8.
    • Author

    • Beddingfield BJ, Iwanaga N, Chapagain PP, Zheng W, Roy CJ, Hu TY, Kolls JK, Bix GJ.